Wikipedia -WSS

Wikipedia

author：knowledge 2025-09-29 20:52:52 - browse：622

Two hands hold a box of four Wegovy pens — first opinion coverage from STAT — Cydni Elledge/The New York Times

The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. This comes on the heels of news that Novo Nordisk halted a clinical trial to test Wegovy’s impact on renal function early because the results they were seeing were so strong.

Yet beneath the hype lies a real fear. Unless we reverse the rising tide of metabolic syndrome, Medicare will be crushed, with tens of millions of Americans having shorter, harder lives. The new drugs offer the first real chance to deploy at scale treatments to halt a seemingly unstoppable trend.

That will be costly. But so is the status quo. Medicare spending on people with advanced metabolic disease is sobering. Beneficiaries with two or more of the costliest conditions — diabetes, heart failure, or chronic kidney disease — comprise just 10% of beneficiaries, according to the NIH’s Renal Data System 2022 Annual Data Report. Yet they account for 25% of total costs. Those with all three conditions are 2% of beneficiaries but almost 7% of costs. And remember, the current cohort of Medicare beneficiaries turned 65 when obesity and diabetes rates were lower, meaning unless we do something dramatic, and fast, these percentages will balloon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： ACIP vaccine advisory panel sees its vacancies filled

hotspot

WSS

Long Covid research funding gets a major boost from NIH

Bernie Sanders gets little from pharma CEOs on drug prices

Abbott's new heart device gets FDA advisory panel nod

AMAs digital advisors table RPM coding reform proposal, again

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Why depression after traumatic brain injury is distinct

entertainment

Wikipedia

entertainment

At least 13 dead in Texas as scorching temps continue

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Medical leaders decry Supreme Court decision on affirmative action

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Hollywood unions extend contract negotiations for actors

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Report cites 'urgent' need to recruit more diverse clinical trial participants

Hepatitis C has a cure — but many Americans still lack access to it

UCLA team creates talking throat patch for voice disorders

knowledge

Why don't Americans have at

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Websites selling Wegovy, Zepbound ingredients targeted by FDA

John Green on his newest strategy for fighting tuberculosis

Amid AI frenzy, a top HHS official's quest to create safeguards

Here’s what’s in the FDA plan to include pregnant women in clinical trials

leisure time

entertainment

hotspot

leisure time